Successful use of obinutuzumab in focal segmental glomerulosclerosis with inadequate response to rituximab: a case report
Frontiers in Nephrology · 03.03.2026 · 6
DOI: 10.3389/fneph.2026.1772736 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Nephrology, online erschienen am 03.03.2026. Verfasst von Andreia Rita Henriques und 4 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Department, Hospitais da Universidade de Coimbra, Unidade Local de Saúde de Coimbra, Coimbra, Portugal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Podocytopathies such as minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) remain therapeutic challenges in adults. Although corticosteroids and rituximab (RTX), a chimeric anti-CD20 monoclonal antibody, are effective in most patients, up to 10% show resistance or relapse despite B-cell depletion. Obinutuzumab (OBZ), a humanized type II anti-CD20 monoclonal antibody, achieves deeper and more sustained B-cell depletion and may overcome RTX inadequate response. Case report A 33-year-old woman presented with nephrotic syndrome (proteinuria 7.1 g/24 h, serum albumin 2.6 g/dL, preserved renal function). Kidney biopsy revealed primary FSGS. She achieved only partial remission with corticosteroids and cyclosporine. RTX (1 g × 2 doses) induced transient peripheral B-cell depletion but no complete remission. A second biopsy excluded chronic changes, and genetic testing for hereditary podocytopathy was negative. Thus 67 weeks after diagnosis and initial treatment with persistent proteinuria > 1g/24 h and hypoalbuminemia, the patient received OBZ (1 g × 2 doses, two weeks apart). Two months later, she achieved complete remission (proteinuria 0.2 g/24 h, serum albumin 3.7 g/dL), with sustained B-cell depletion and no adverse events. A repeat administration of OBZ (1 g) was performed 10 months later due to B-cell repopulation, rising proteinuria (0.6 g/24 h), and mild hypoalbuminemia (serum albumin 3.4 g/dL), successfully re-inducing complete remission (proteinuria 0.2 g/24 h, serum albumin 3.8 g/dL).
Discussion
This case illustrates the potential of OBZ as an effective therapeutic option in podocytopathies with RTX inadequate response. The superior efficacy of OBZ may result from enhanced antibody-dependent cellular cytotoxicity, depletion of tissue-resident B cells, and reduced immunogenicity compared with RTX. OBZ may thus offer an alternative in refractory MCD/FSGS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nephrology Department, Hospitais da Universidade de Coimbra, Unidade Local de Saúde de Coimbra, Coimbra, Portugal.
- University of Coimbra, Faculty of Medicine, Coimbra, Portugal.
Zitieren
APA
Henriques, A. R., Venda, J., Ferreira, E., Oliveira, N., & Sá, H. (2026). Successful use of obinutuzumab in focal segmental glomerulosclerosis with inadequate response to rituximab: a case report. Frontiers in Nephrology, 6. https://doi.org/10.3389/fneph.2026.1772736
Vancouver
Henriques AR, Venda J, Ferreira E, Oliveira N, Sá H. Successful use of obinutuzumab in focal segmental glomerulosclerosis with inadequate response to rituximab: a case report. Frontiers in Nephrology. 2026;6. doi:10.3389/fneph.2026.1772736
BibTeX
@article{Henriques2026,
author = {Henriques, Andreia Rita and Venda, João and Ferreira, Emanuel and Oliveira, Nuno and Sá, Helena},
title = {Successful use of obinutuzumab in focal segmental glomerulosclerosis with inadequate response to rituximab: a case report},
journal = {Frontiers in Nephrology},
year = {2026},
volume = {6},
doi = {10.3389/fneph.2026.1772736}
}
EUVIMED